# Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

> **NCT06600841** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer (PROC)
- Immunotherapy

## Interventions

- **DRUG:** Immunotherapy（Adebrelimab）
- **DRUG:** immunotherapy（Adebrelimab）

## Key facts

- **NCT ID:** NCT06600841
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600841, "Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06600841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*